Miniature bovine pancreatic trypsin inhibitors (m-BPTIs) of the West Nile virus NS2B-NS3 protease

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 31, Issue , 2016, Pages 194-200

  Ang, Melgious J Y ^a   Lim, Huichang A ^a   Poulsen, Anders ^a   Wee, John Liang Kuan ^a   Ng, Fui Mee ^a   Joy, Joma ^a   Hill, Jeffrey ^a   Chia, C S Brian ^a  

^a Agency for Science   (Singapore)

Author keywords

Aprotinin; BPTI; NS3 protease; peptide; West Nile virus

Indexed keywords

AMINO ACID; ANTIVIRUS AGENT; APROTININ; CELL PENETRATING PEPTIDE; CYCLOPEPTIDE; DISULFIDE; NONA DEXTRO ARGININE NH2 PEPTIDE; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; PROTEINASE INHIBITOR; TRYPTASE; UNCLASSIFIED DRUG; NS2B PROTEIN, FLAVIVIRUS; NS3 PROTEIN, FLAVIVIRUS; RNA HELICASE; SERINE PROTEINASE; TRYPSIN; TRYPSIN INHIBITOR; VIRAL PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; IC50; LUNG PARENCHYMA; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; WEST NILE VIRUS; ANIMAL; ANTAGONISTS AND INHIBITORS; BOVINE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MICROBIAL SENSITIVITY TEST; STRUCTURE ACTIVITY RELATION; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

ANIMALS; CATTLE; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; RNA HELICASES; SERINE ENDOPEPTIDASES; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPSIN; TRYPSIN INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS; WEST NILE VIRUS;

EID: 84973137257     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756366.2016.1190713     Document Type: Article

References (28)

1. Colpitts TM, Conway MJ, Montgomery RR, Fikrig E., West Nile virus:biology, transmission, and human infection. Clin Microbiol Rev 2012;25:635–48
2. Solomon T., Flavivirus encephalitis. N Engl J Med 2004;351:370–8
3. Johnson RT., West Nile virus in the US and abroad. Curr Clin Top Infect Dis 2002;22:52–60
4. Gould LH, Fikrig E., West Nile virus:a growing concern? J Clin Invest 2004;113:1102–7
5. Kramer LD, Li J, Shi PY., West Nile virus. Lancet Neurol 2007;6:171–81
6. Gray TJ, Webb CE., A review of the epidemiological and clinical aspects of West Nile virus. Int J Gen Med 2014;7:193–203
7. www.cdc.gov/ncidod/dvbid/westnile/index.htm
8. Kaiser J. Public health. Outbreak pattern stymies vaccine work. Science 2012;337:1030
9. Diamond MS., Progress on the development of therapeutics against West Nile virus. Antiviral Res 2009;83:214–27
10. Mukhopadhyay S, Kuhn RJ, Rossmann MG., A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 2005;3:13–22
11. Chappell KJ, Stoermer MJ, Fairlie DP, Young PR., Insights to substrate binding and processing by West Nile virus NS3 protease through combined modeling, protease mutagenesis and kinetic studies. J Biol Chem 2006;281:38448–58
12. Chappell KJ, Stoermer MJ, Fairlie DP, Young PR., West Nile virus NS2B/NS3 protease as an antiviral target. Curr Med Chem 2008;15:2771–84
13. Radichev I, Shiryaev SA, Aleshin AE, et al. Structure-based mutagenesis identifies important novel determinants of the NS2B cofactor of the West Nile virus two-component NS2B-NS3 proteinase. J Gen Virol 2008;89:636–41
14. Poulsen A, Kang C, Keller TH., Drug design for Flavivirus proteases:what are we missing? Curr Pharm Des 2014;20:3422–7
15. Kunitz M, Northrup J. Isolation from beef pancreas of crystalline trypsinogen, trypsin, a trypsin inhibitor, and an inhibitor-trypsin compound. J Gen Physiol 1936;19:991–1007
16. Kassell B, Radicevic M, Ansfield MJ, Laskowski M., The basic trypsin inhibitor of bovine pancreas. IV. The linear sequence of the 58 amino acids. Biochem Biophys Res Commun 1965;18:255–8
17. Ascenzi P, Bocedi A, Bolognesi M, et al. The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor):a milestone protein. Curr Protein Pept Sci 2003;4:231–51
18. Robin G, Chappell K, Stoermer MJ, et al. Structure of West Nile virus NS3 protease:ligand stabilization of the catalytic conformation. J Mol Biol 2009;385:1568–77
19. Aleshin AE, Shiryaev SA, Strongin AY, Liddington RC., Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Sci 2007;16:795–806
20. Nall TA, Chappell KJ, Stoermer MJ, et al. Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease. J Biol Chem 2004;279:48535–42
21. Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL., Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 2001;105:6474–87
22. Polak E, Ribière G., Rev. Francaise Informat Recherche Opérationelle, Série Rouge. Note sur la Convergence de Directions Conjuguée 1969;16:35–43
23. Hasel W, Hendrickson TF, Still WC., A rapid approximation to the solvent accessible surface areas of atoms. Tetrahedron Comput Methodol 1988;1:103–16
24. Chang CA, Chen W, Gilson MK., Ligand configurational entropy and protein binding. Proc Natl Acad Sci USA 2007;104:1534–9
25. Zhirnov OP, Klenk HD, Wright PF., Aprotinin and similar protease inhibitors as drugs against influenza. Antiviral Res 2011;92:27–36
26. Takeda-Shitaka M, Kamiya K, Miyata T, et al. Structural studies of the interactions of normal and abnormal human plasmins with bovine basic pancreatic trypsin inhibitor. Chem Pharm Bull 1999;47:322–8
27. Chen Z, Bode W. Refined 2.5 Å X-ray crystal structure of the complex formed by porcine kallikrein A and the bovine pancreatic trypsin inhibitor. J Mol Biol 1983;164:283–311
28. www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM142741.pdf